Institutional Biosafety Committee
Meeting Minutes

The meeting was called to order on 12/23/2025 at 11:30AM. A quorum was present. The meeting was held via Zoom and in-person (Melville Library – 5th Floor, Room W5530). The meeting was open.

Attendance
Voting Members Present:
Dafang Wang
Hwan Kim
Rachel Brownlee
Jorge Escobar
Nicholas Carpino
Jeronimo Cello
Christopher Kuhlow

Non-Voting Attendees, Staff and Guests Present:
Aimee Minton
Lu-Ann Kozlowski
Terrence Rusch

Recording:
Erin Augello

Items
1. Meeting called to order at 11:30AM

2. Next meeting date and general announcements
The next meeting date is 1/27/2026. Dr. Carpino surveyed the assembled group to assess any conflict of interest or quorum issues. Members should recuse themselves and leave the room or Zoom meeting during the review of a study on which they have a conflict of interest.

3. Review of minutes from last meeting
Review type: **Full Committee Review**

Action: **Approved**
Effective date: **12/23/2025**
Vote: **Total = 7; For = 7; Opposed = 0; Abstained = 0**

4. Continuing reviews requiring IBC review
This section was reviewed and noted by the committee.

5. New studies for committee review

a. PROTO202500040 Inhibiting PCa bone destruction by DABDs

PI:	Raymond Bergan
Submission Type:	Initial Protocol
Safety Review Type:	Biosafety
Funding:	Name: Stony Brook Foundation, Grant Office ID: 951970, Funding Source ID: Name: Research Foundation for The State University of New York, Grant Office ID: 1200126-1-93121, Funding Source ID:
Training:	Training is not up to date. Staff member requires ELS 002, ELS 003, EOS 004, ENV 001, ENV 005.
Applicable Section of the NIH Guidelines that the Research Falls Under	Section IIID
Containment Conditions:	BSL-2

Determination: Modifications Required
Modifications (If Applicable):
i. Training is not up to date. Bergan requires ELS 002, ELS 003, EOS 004, ENV 001, ENV 005.
ii. In Section: Basic Information
Item 1. In the summary, please include a description of the rsNAM work associated with this protocol.
iii. In Section: Funding sources
Item 1. Please provide the requested information
iv. In Section: Biosafety summary
Item 1. Please select rsNAM from the drop-down menu and complete the corresponding sections with appropriate information. In particular, the sections on rsNAM 'usage' and 'work description' need to be included.
v. In Section: Tissues, Blood, or Body Fluids
Item 1. Do not include cell line information here. Cell line information is reserved for the 'Primary Cells or Cell Lines' page.
vi. In Section: Primary Cells or Cell Lines.
Item 1. Mouse cell lines are indicated in previous section. Please list them in this section.
vii. In Section: Risk Group and Containment Practices
Item 2 Change RG2 to RG3, due to use of lentivirus vector.
viii. In Section: Exposure Assessment and Protective Equipment

Item 1. The response addresses perceived risk rather than the potential consequences of exposure or release, as requested. The protocol involves human cell lines, which may harbor bloodborne pathogens, and lentiviral vectors, which carry inherent consequences of accidental exposure, including potential delivery of integrating viral genomes, insertional mutagenesis, and the theoretical presence of replication-competent lentivirus.
The PI should revise this section to include information related to possible consequences of exposure to viruses and potential bloodborne pathogens. Avoid use of non-specific descriptive language such as “mild irritation”.
Item 4. Please complete this subsection regarding certification of BSC.

Effective Date: 12/25/2025
Project Expiration: 12/24/2026

Votes:

For:	7
Against:	0
Recused:	0
Absent:	1
Abstained:	0

b. PROTO202500043 AAV-Injected Osteoporosis Model for Testing Metal Ion Treatment

PI:	Donghui Zhu
Submission Type:	Initial Protocol
Safety Review Type:	Biosafety
Funding:	Name: National Institute on Aging, Grant Office ID: 157611, Funding Source ID: AG064798
Training:	PI and all laboratory staff have been trained
Applicable Section of the NIH Guidelines that the Research Falls Under	Section IIID
Containment Conditions:	BSL-2

Determination: Modifications Required
Modifications (If Applicable):
i. In Section: Biosafety Summary
Item 1. Due to use of bacteria and cell lines, from the drop down menu select ‘Bacteria, Yeast, etc.’ and ‘Cell Lines etc.’ options and provide the requested information
ii. In Section: Viruses or Prions
Item 1 AAV is BSL-1 unless a helper virus is used then it is BSL-2.
iii. In Section: Biohazards
Item 1 AAV is BSL-1 unless a helper virus is used then it is BSL-2.
iv. In Section: Recombinant or Synthetic Nucleic Acid Work Description
Item 9. Check "No" here because no helper virus is used.
Item 12. Check "No" here because no Adenovirus vector is used.
v. In Section: Exposure Assessment and Protective Equipment

Item 1. The PI does not address the potential consequences of exposure to replication-defective AAV, including the possibility of insertional mutagenesis following infection. In addition, potential consequences of exposure to bloodborne pathogens from use of human cell lines (HEK293) needs to be acknowledged and described.
Item 4. Since manipulation of viral vectors requires use of a certified BSC, the PI should complete the information of BSC including certification status.

Effective Date: 12/25/2025
Project Expiration: 12/24/2026

Votes:

For:	7
Against:	0
Recused:	0
Absent:	1
Abstained:	0

6. Amendments requiring IBC review

a. AMEND202500130 Update Hood Certification Date

PI:	Peter Tonge
Submission Type:	Amendment
Safety Review Type:	Biosafety
Funding:	None
Training:	PI and all laboratory staff have been trained
Applicable Section of the NIH Guidelines that the Research Falls Under	Section IIID
Containment Conditions:	BSL-2

Determination: Modifications Required
Modifications (If Applicable):
i. In Section: Basic Information
Item 4. The research summary is too brief and lacks essential information. Please add additional details in the summary describing rsNAM work to be performed, such which proteins will be genetically modified, target cells, etc. etc.
ii. In Section: Primary Cells or Cell Lines
Item 2. E coli should not be listed here.
iii. In Section: Recombinant or Synthetic Nucleic Acid Usage
Item 1. IIID applies, please indicate “Yes”.
iv. In Section: Recombinant or Synthetic Nucleic Acid Work Description
Item 1. Most of the safety information in this section can be removed, as it does not address the requested information, i.e.it does not describe the work being performed. Please add more detail describing the rsNAM work that will be performed.
Item 3. Most of the information provided does not address the question and should be added to item #1 in this section. Here, please address describe the biological activity and species of origin of each target gene (MCL1, BTK, SMG1, LpxC).

v. In Section: Risk Group and Containment Practices
Item 1. Change to "RG-3" because the lentivirus is derived from HIV.
vi. In Section: Exposure Assessment and Protective Equipment
Item 1. As requested, please acknowledge the risk of replication-competent lentivirus generation and insertional mutagenesis. These risks are inherent to the lentiviral vector system and should be addressed regardless of the oncogenic potential of the inserted genes. Further, use of VSV-G pseudo typing confers broad host range, increasing the potential for accidental exposure.
Item 4C. Certification BSC expires soon. Annual BSC certification is required for approval of the Protocol. Please recertify BSC and report date of certification.

Effective Date: 12/12/2025
Project Expiration: 12/11/2026

Votes:

For:	7
Against:	0
Recused:	0
Absent:	1
Abstained:	0

b. AMEND202500131 In vivo and in vitro assessment of p53 and p73 functions

PI:	Alice Nemajerova
Submission Type:	Amendment
Safety Review Type:	Biosafety
Funding:	None
Training:	PI and all laboratory staff have been trained
Applicable Section of the NIH Guidelines that the Research Falls Under	Section IIID
Containment Conditions:	BSL-2

Determination: Modifications Required
Modifications (If Applicable):
i. In Section: Basic Information
Item 4. Please add more detail to the summary including a description of rsNAM work.
ii. In Section: Primary Cells or Cell Lines
Item 1. Provide the Category option for non-human cell line KPC4.
iii. In Section: Viruses or Prions
Item 1. BSL for AAV is BSL-1.
iv. In Section: Biohazards
Item 1. BSL for AAV is BSL-1.
v. In Section: Exposure Assessment and Protective Equipment
Item 1. Please address the potential consequences of exposure to replication-defective AAV vectors, which can still infect cells and deliver genetic material with the possibility of insertional mutagenesis. Also, Please address the potential consequences of exposure to human cell lines, which may harbor bloodborne pathogens.

Item 4. Certification of BSC has expired. Please recertify BSC and report certification date.
vi. In Section: Waste Management
Item 1. The described procedures require clarification. If semi-liquid biological waste (e.g., tissue culture) is chemically disinfected with 10% bleach, an appropriate contact time (typically ≥30 minutes) should be specified. After effective chemical inactivation, liquid waste is normally disposed of down the drain in accordance with institutional and EH&S guidance, while empty culture vessels and solid materials are disposed of as RMW.
Item 3. The response does not describe the initial decontamination procedures to be taken in the event of a biological accident. Immediate actions (e.g., spill containment, application of appropriate disinfectant, evacuation if necessary) should be described first. Notification of EH&S and Occupational Health should occur after initial containment and decontamination steps are initiated.

Effective Date: 12/25/2025
Project Expiration: 12/24/2026

Votes:

For:	7
Against:	0
Recused:	0
Absent:	1
Abstained:	0

c. AMEND202500136 Change Personnel

PI:	Roger Sher
Submission Type:	Amendment
Safety Review Type:	Biosafety
Funding:	None
Training:	PI and all laboratory staff have been trained
Applicable Section of the NIH Guidelines that the Research Falls Under	Section IIID
Containment Conditions:	BSL-2

Determination: Modifications Required
Modifications (If Applicable):
i. In Section: Funding resources
Item 1. Please provide requested funding information, including sponsor's funding ID number and grants office ID number.
ii. In Section: Viruses or Prions
Item 1. Please remove all biosafety considerations/discussion that is listed the “Activities” column.
iii. In Section: Recombinant or Synthetic Nucleic Acid Work Usage
Item 1. Please indicate Section III-D here.
iv. In Section: Genetically modified animals: DNA Source
Item 5. Change to "Yes" (due to use of lentivirus).
v. In Section: Rodent gene transfer: virus

Item 2. Change to "Yes" (due to use of lentivirus).
vi. In Section: Risk Group and Containment Practices
Item 2. For NIH Guidelines section, change to BL-2.
vii. In Section: Exposure Assessment and Protective Equipment
Item 4C. Annual BSC certification is out of date. Please recertify and provide new certification date.
viii. In Section: Waste Management
Item 1. Please provide a more comprehensive description of the process in place for decontaminating biological waste.

Effective Date: 2/28/2026
Project Expiration: 2/27/2027

Votes:

For:	7
Against:	0
Recused:	1
Absent:	0
Abstained:	0

d. AMEND202500137 Monitor and manipulate gene expression in cultured cells and mice

PI:	Chengfeng Yang
Submission Type:	Amendment
Safety Review Type:	Biosafety
Funding:	None
Training:	PI and all laboratory staff have been trained
Applicable Section of the NIH Guidelines that the Research Falls Under	Section IIID
Containment Conditions:	BSL-2

Determination: Modifications Required
Modifications (If Applicable):
i. In Section: Tissues, Blood, or Body Fluid
Item 3. Please provide a more accurate estimation of quantity of tissues or volumes of fluids to be used.
ii. In Section: Bacteria, Yeasts, Fungi, or Parasites
Item 1. E. coli should be listed as "BSL-1".
iii. In Section: Viruses or Prions
Item 1. AAV can be listed as "BSL-1" unless a helper virus is used. However, PI will use AAV2/6-deltap63, which is described as a lineage/basal epithelial “lineage survival” factor. Thus, overexpression can support proliferation/survival in some epithelial contexts, but it is not generally categorized as an oncogene requiring automatic BSL-2 on that basis alone. Therefore, conducting the work at BSL-2 is an acceptable conservative approach and provides an added margin of safety. This is at the discretion of the PI.
iv. In Section: Biohazards
Item 1. E. coli should be listed as "BSL-1".

v. In Section: Rodent Gene Transfer: Virus
Item 2. Change to 'Yes' for infection of mouse with AAV2/6-deltap63.
vi. In Section: Waste Management
Item 1. Indicate concentration of bleach.

Effective Date: 2/1/2026
Project Expiration: 1/31/2027

Votes:

For:	7
Against:	0
Recused:	1
Absent:	0
Abstained:	0

7. Review of incidents
None

8. Review of other agenda items
None

9. Inspection results
All inspections and responses were summarized by Mr. Kuhlow and reviewed and noted by the committee.

10. Discussion items/readings (major and minor points of order)
None

11. Meeting adjourned at **12:22AM**